Edgardo S. Santos, MD, FACP, FASCO, a hematologist and medical oncologist, discussed how artificial intelligence (AI) is revolutionizing lung cancer care by analyzing imaging data to detect malignancies and interstitial lung disease, while stressing the importance of regulation to ensure its safe and ethical use.
Artificial intelligence is playing a growing role in advancing lung cancer care, particularly in diagnostics and treatment. Edgardo S. Santos, MD, FACP, FASCO, a hematologist and medical oncologist at the Oncology Institute of Hope and Innovation, highlighted artificial intelligence's potential in analyzing imaging data, such as identifying irregularities in x-rays or computer tomography (CT) scans that may indicate malignancies, as well as detecting patterns of interstitial lung disease caused by medication or radiation.
Additionally, artificial intelligence can predict driver mutations by analyzing biopsy images, potentially eliminating the need for molecular testing. While acknowledging artificial intelligence's vast potential, Santos emphasized the importance of regulation to ensure its safe and ethical use in health care.
This transcript has been lightly edited for clarity.
Transcript
How are artificial intelligence and machine learning being used to advance lung cancer care, from diagnosis to treatment?
Well, that's another hot topic right now: artificial intelligence. Artificial intelligence can be applied anywhere in any single aspect of our life, from our daily activities, finance, agriculture, banking, and also in health care. So, again, just talking about lung cancer, artificial intelligence will have a many utilities. The recent ones that I have learned about, for example, is in the imaging setting. Artificial intelligence collects several data from thousands of imaging and artificial intelligence can predict, for example, if an irregular x-ray or CT scan a could predict that a patient may have a malignant disease ongoing and could perhaps alert the physician that to either [follow it closely] or perform a biopsy.
Another example for when [artificial intelligence is] collecting thousands of images, there is a problem that we call in lung cancer "interstitial lung disease," which basically is an inflammatory pattern. Today, there are different patterns of interstitial lung disease, and sometimes we have difficulty to seeing it because of radiation oncology or inflammation in the lung field or because of the medication that the patient is getting. And this is very important because it's very tricky [to figure out] how we are going to handle this issue with our patient. So artificial intelligence is collecting these thousands of inflammatory process in the lung that they can predict if this is secondary to the medication or secondary to radiation therapy, and that will help the clinician, again, to manage the patient.
Believe it or not, there is another technology in artificial intelligence collecting thousands and thousands of biopsies seen on a microscope and just by looking at the parent of the adenocarcinoma and how the cells look, the artificial intelligence can predict if the patient has a particular driver mutation. Amazing! So without doing a molecular testing and just by looking the pattern and the structure of the cells, [the artificial intelligence] can predict that.
So you can see how the artificial intelligence by collecting thousands of [pieces of] information can help us in the future. And this is going to be the future. However, as you heard in the news, artificial intelligence must be regulated, because in the wrong hands it can hurt people. So that's another issue that is not for us. But certainly, [artificial intelligence] has a lot of potential that, as humans, we need to be savvy about how to handle it. And [we need to figure out] how to moderate, utilize, and legislate that kind of advancement in technology in general.
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Multidisciplinary Approaches to Pediatric Obstructive Sleep Apnea: A Review of Respiratory Therapies
August 13th 2025The treatment of pediatric obstructive sleep apnea syndrome is moving toward a personalized, multidisciplinary approach that combines surgical options with a growing number of nonsurgical alternatives, to better address the unique needs of each child.
Read More